Genpharmasec Limited (BOM:531592)
India · Delayed Price · Currency is INR 1.400
+0.060 (4.48%)
At close: Feb 12, 2026
Genpharmasec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 985.18 | 337.22 | 304.06 | 255.16 | 273.21 | 213.08 |
| 985.18 | 337.22 | 304.06 | 255.16 | 273.21 | 213.08 | |
Revenue Growth (YoY) | 229.38% | 10.91% | 19.16% | -6.61% | 28.22% | 29.13% |
Cost of Revenue | 913.72 | 295.48 | 242.33 | 233.97 | 265.65 | 192 |
Gross Profit | 71.46 | 41.74 | 61.73 | 21.18 | 7.55 | 21.07 |
Selling, General & Admin | 31.52 | 10.29 | 9.18 | 6.83 | 3.59 | 2.9 |
Other Operating Expenses | 57.43 | 30.81 | 52.09 | 11.67 | 9.18 | 6.23 |
Operating Expenses | 106.44 | 49.21 | 61.69 | 18.7 | 12.91 | 9.25 |
Operating Income | -34.98 | -7.47 | 0.04 | 2.48 | -5.36 | 11.82 |
Interest Expense | -8.65 | -4.34 | -4.09 | -0.56 | - | - |
Interest & Investment Income | 2.35 | 2.35 | 0 | 0.31 | 0.65 | 3.28 |
Currency Exchange Gain (Loss) | 0.96 | 0.96 | 1.83 | 0.55 | 0.16 | - |
Other Non Operating Income (Expenses) | 0.16 | -0 | -0 | 0.04 | 0.11 | - |
EBT Excluding Unusual Items | -40.17 | -8.51 | -2.22 | 2.82 | -4.43 | 15.1 |
Gain (Loss) on Sale of Investments | 27.31 | 27.31 | 4.73 | - | - | - |
Pretax Income | -12.85 | 18.8 | 2.51 | 2.82 | -4.43 | 15.1 |
Income Tax Expense | 0.66 | 6.49 | 4.2 | -8.43 | -2.34 | 2.52 |
Net Income | -4.58 | 12.31 | -1.69 | 11.25 | -2.09 | 12.57 |
Net Income to Common | -4.58 | 12.31 | -1.69 | 11.25 | -2.09 | 12.57 |
Net Income Growth | - | - | - | - | - | 24.57% |
Shares Outstanding (Basic) | 449 | 554 | 307 | 277 | 277 | 271 |
Shares Outstanding (Diluted) | 449 | 554 | 307 | 277 | 277 | 271 |
Shares Change (YoY) | -25.74% | 80.25% | 10.96% | - | 2.06% | -46.25% |
EPS (Basic) | -0.01 | 0.02 | -0.01 | 0.04 | -0.01 | 0.05 |
EPS (Diluted) | -0.01 | 0.02 | -0.01 | 0.04 | -0.01 | 0.05 |
EPS Growth | - | - | - | - | - | 131.76% |
Free Cash Flow | - | -27.19 | -29.64 | -30.76 | -24.25 | -21.47 |
Free Cash Flow Per Share | - | -0.05 | -0.10 | -0.11 | -0.09 | -0.08 |
Gross Margin | 7.25% | 12.38% | 20.30% | 8.30% | 2.77% | 9.89% |
Operating Margin | -3.55% | -2.22% | 0.01% | 0.97% | -1.96% | 5.55% |
Profit Margin | -0.46% | 3.65% | -0.56% | 4.41% | -0.77% | 5.90% |
Free Cash Flow Margin | - | -8.06% | -9.75% | -12.05% | -8.88% | -10.08% |
EBITDA | -29.07 | -4.02 | 0.21 | 2.68 | -5.21 | 11.94 |
EBITDA Margin | -2.95% | -1.19% | 0.07% | 1.05% | -1.91% | 5.61% |
D&A For EBITDA | 5.91 | 3.45 | 0.17 | 0.2 | 0.14 | 0.13 |
EBIT | -34.98 | -7.47 | 0.04 | 2.48 | -5.36 | 11.82 |
EBIT Margin | -3.55% | -2.22% | 0.01% | 0.97% | -1.96% | 5.55% |
Effective Tax Rate | - | 34.52% | 167.56% | - | - | 16.70% |
Revenue as Reported | 1,016 | 367.84 | 310.62 | 256.16 | 274.13 | 216.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.